5 January 2015 - Deborah Wilkes
Archived
Omega Pharma is in-licensing the OTC rights to BioLineRx's skin lesion treatment, BL-5010, in Europe, Australia and a number of additional countries. Rights in the US and the rest of the world will be retained by the Israeli product development company.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.